CN110248944A - 非肽催产素受体激动剂 - Google Patents

非肽催产素受体激动剂 Download PDF

Info

Publication number
CN110248944A
CN110248944A CN201780085825.XA CN201780085825A CN110248944A CN 110248944 A CN110248944 A CN 110248944A CN 201780085825 A CN201780085825 A CN 201780085825A CN 110248944 A CN110248944 A CN 110248944A
Authority
CN
China
Prior art keywords
substituted
unsubstituted
alkyl
group
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780085825.XA
Other languages
English (en)
Chinese (zh)
Inventor
M·卡修
W·约尔根森
E·韦里
T·雷凯
M·博恩
I·麦格雷戈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Golden Oaks Treatment Ltd
Original Assignee
University of Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016905126A external-priority patent/AU2016905126A0/en
Application filed by University of Sydney filed Critical University of Sydney
Publication of CN110248944A publication Critical patent/CN110248944A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
CN201780085825.XA 2016-12-12 2017-12-12 非肽催产素受体激动剂 Pending CN110248944A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016905126A AU2016905126A0 (en) 2016-12-12 Non-peptide oxytocin receptor agonists
AU2016905126 2016-12-12
PCT/AU2017/051371 WO2018107216A1 (en) 2016-12-12 2017-12-12 Non-peptide oxytocin receptor agonists

Publications (1)

Publication Number Publication Date
CN110248944A true CN110248944A (zh) 2019-09-17

Family

ID=62557695

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780085825.XA Pending CN110248944A (zh) 2016-12-12 2017-12-12 非肽催产素受体激动剂

Country Status (19)

Country Link
US (2) US11491165B2 (https=)
EP (2) EP4494705A3 (https=)
JP (3) JP7089649B2 (https=)
KR (1) KR102561721B1 (https=)
CN (1) CN110248944A (https=)
AU (1) AU2017377653B2 (https=)
BR (1) BR112019012049A2 (https=)
CA (1) CA3046809A1 (https=)
DK (1) DK3551631T3 (https=)
ES (1) ES3001195T3 (https=)
FI (1) FI3551631T3 (https=)
HU (1) HUE070078T2 (https=)
IL (1) IL267276B2 (https=)
MX (1) MX2019006942A (https=)
PL (1) PL3551631T3 (https=)
PT (1) PT3551631T (https=)
RU (1) RU2019120162A (https=)
SI (1) SI3551631T1 (https=)
WO (1) WO2018107216A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220079953A1 (en) * 2018-11-23 2022-03-17 The University Of Sydney Methods for management of weight
KR20220063198A (ko) * 2019-09-06 2022-05-17 키녹시스 테라퓨틱스 피티와이 리미티드 아편유사제 금단의 치료
JP2022548581A (ja) 2019-09-13 2022-11-21 オリゲニス ゲーエムベーハー 例えば自己免疫疾患の処置のための、ＬＲＲＫ２、ＮＵＡＫ１および／またはＴＹＫ２キナーゼモジュレータとしての１，４－ジヒドロベンゾ［ｄ］ピラゾロ［３，４－ｆ］［１，３］ジアゼピン誘導体および関連する化合物
JP2023552485A (ja) * 2020-12-14 2023-12-15 キノシス・セラピューティクス・ピーティーワイ・リミテッド オキシトシン受容体モジュレーター
AU2022240104A1 (en) * 2021-03-18 2023-10-05 Kinoxis Therapeutics Pty Ltd Methods of treatment

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3770762A (en) * 1972-08-29 1973-11-06 Parke Davis & Co Diazepine compounds and methods for their production
CN1543467A (zh) * 2001-08-16 2004-11-03 催产素兴奋剂
CN1606553A (zh) * 2001-06-25 2005-04-13 凡林有限公司 催产素激动药
CN1751050A (zh) * 2003-02-14 2006-03-22 凡林有限公司 作为催产素激动剂和加压素拮抗剂的苯甲酰胺衍生物
CN1842580A (zh) * 2003-07-01 2006-10-04 光学转变公司 光致变色化合物
US20070197608A1 (en) * 2003-09-05 2007-08-23 Ferring B.V. Piperazines as oxytocin agonists
CN101203516A (zh) * 2005-04-05 2008-06-18 法马科皮亚公司 用于免疫抑制的嘌呤及咪唑并吡啶衍生物
CN101296929A (zh) * 2005-10-24 2008-10-29 惠氏公司 适用作催产素受体促效剂的三环化合物
CN101563347A (zh) * 2004-08-24 2009-10-21 万梯雅公司 血管升压素V1a拮抗剂
CN101899049A (zh) * 2004-10-13 2010-12-01 霍夫曼-拉罗奇有限公司 二取代吡唑并苯并二氮杂*类

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR002459A1 (es) 1995-01-17 1998-03-25 American Cyanamid Co Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
US5536718A (en) * 1995-01-17 1996-07-16 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
WO2008103382A1 (en) * 2007-02-20 2008-08-28 Sergey Kozmin Method for assembling high-purity chemical libraries, compounds suppressing acetyl coenzyme a carboxylase activities discovered by same
GB0903493D0 (en) * 2009-02-27 2009-04-08 Vantia Ltd New compounds
US10508108B2 (en) * 2014-12-05 2019-12-17 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant IDH enzymes
PL3328864T3 (pl) * 2015-07-06 2023-02-27 Kinoxis Therapeutics Pty Ltd Związki i kompozycje terapeutyczne do leczenia zaburzeń społecznych i zaburzeń związanych z używaniem substancji psychoaktywnych

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3770762A (en) * 1972-08-29 1973-11-06 Parke Davis & Co Diazepine compounds and methods for their production
CN1606553A (zh) * 2001-06-25 2005-04-13 凡林有限公司 催产素激动药
CN1543467A (zh) * 2001-08-16 2004-11-03 催产素兴奋剂
CN1751050A (zh) * 2003-02-14 2006-03-22 凡林有限公司 作为催产素激动剂和加压素拮抗剂的苯甲酰胺衍生物
CN1842580A (zh) * 2003-07-01 2006-10-04 光学转变公司 光致变色化合物
US20070197608A1 (en) * 2003-09-05 2007-08-23 Ferring B.V. Piperazines as oxytocin agonists
CN101563347A (zh) * 2004-08-24 2009-10-21 万梯雅公司 血管升压素V1a拮抗剂
CN101899049A (zh) * 2004-10-13 2010-12-01 霍夫曼-拉罗奇有限公司 二取代吡唑并苯并二氮杂*类
CN101203516A (zh) * 2005-04-05 2008-06-18 法马科皮亚公司 用于免疫抑制的嘌呤及咪唑并吡啶衍生物
CN101296929A (zh) * 2005-10-24 2008-10-29 惠氏公司 适用作催产素受体促效剂的三环化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARIE-CELINE FRANTZ等，: ""Subtlety of the Structure-Affinity and Structure-Efficacy Relationships around a Nonpeptide Oxytocin Receptor Agonist"", 《J. MED. CHEM.》 *
WILLIAM T. JORGENSEN等，: ""Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors"", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *

Also Published As

Publication number Publication date
KR102561721B1 (ko) 2023-07-28
US20200000823A1 (en) 2020-01-02
IL267276B1 (en) 2024-05-01
BR112019012049A2 (pt) 2019-11-12
EP3551631A1 (en) 2019-10-16
AU2017377653B2 (en) 2022-04-21
JP2024107136A (ja) 2024-08-08
EP3551631A4 (en) 2020-07-15
JP2022097655A (ja) 2022-06-30
RU2019120162A (ru) 2021-01-12
ES3001195T3 (es) 2025-03-04
PL3551631T3 (pl) 2025-03-24
HUE070078T2 (hu) 2025-05-28
IL267276B2 (en) 2024-09-01
DK3551631T3 (en) 2025-02-17
US20230330103A1 (en) 2023-10-19
CA3046809A1 (en) 2018-06-21
MX2019006942A (es) 2019-10-21
EP3551631B1 (en) 2024-11-13
FI3551631T3 (fi) 2025-01-16
EP4494705A3 (en) 2025-04-02
EP3551631B9 (en) 2025-02-26
JP2020500924A (ja) 2020-01-16
US11491165B2 (en) 2022-11-08
RU2019120162A3 (https=) 2021-01-28
WO2018107216A1 (en) 2018-06-21
IL267276A (en) 2019-08-29
PT3551631T (pt) 2024-12-10
SI3551631T1 (sl) 2025-03-31
AU2017377653A1 (en) 2019-07-11
KR20190091534A (ko) 2019-08-06
EP4494705A2 (en) 2025-01-22
JP7089649B2 (ja) 2022-06-23
NZ754890A (en) 2025-03-28

Similar Documents

Publication Publication Date Title
CN104981470B (zh) 氨基取代的咪唑并[1,2‑a]吡啶羧酰胺和它们的用途
JP2024107136A (ja) 非ペプチドオキシトシン受容体アゴニスト
CN104892502B (zh) 作为醛固酮合酶抑制剂的芳基吡啶
CN105492437B (zh) 取代的苯并呋喃基和苯并噁唑基化合物及其用途
JP2016000754A (ja) Ｎｈ酸性化合物のプロドラッグ：エステル、カルボネート、カルバメートおよびホスホネートの誘導体
MX2013008111A (es) Derivados de oxazina y su uso en el tratamiento de transtornos neurologicos.
TW201605850A (zh) 經取代吡唑并［１，５－ａ］吡啶－３－羧醯胺類及其用途
TW201514136A (zh) 組蛋白去乙醯酶抑制劑及組成物，暨其使用之方法
TW201245151A (en) Asymmetric ureas and medical uses thereof
CN108779119A (zh) 嘧啶及其变体、及其用途
TW201609698A (zh) 三環磺醯胺衍生物
CN109863139A (zh) 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
TW202440553A (zh) 作為at2r拮抗劑的雜環化合物
TWI710559B (zh) 新吡啶陽離子化合物、包含該化合物的藥學組成物、其用途及其製備方法
JP2014518281A (ja) 電位依存性ナトリウムチャネル遮断薬
CN114008040B (zh) 用于调节fxr的化合物
TW200824689A (en) Novel compounds
CN110461835A (zh) 异噁唑甲酰胺化合物及其用途
JP2000506524A (ja) フィブリノーゲン受容体拮抗剤であるＮ―［（Ｒ）―１―｛３―（４―ピペリジル）プロピオニル｝―３―ピペリジルカルボニル］―２（Ｓ）―アセチルアミノ―β―アラニン
CN112118891A (zh) 作为流感病毒复制抑制剂的稠和多环吡啶酮化合物
HK40014275A (en) Non-peptide oxytocin receptor agonists
CN107207477A (zh) 用于治疗病毒性疾病的亚氨基糖
JPWO2004080965A1 (ja) ニューロペプチドｆｆ受容体拮抗剤
EP1498138A1 (en) Preventives for hiv infection
WO2022161416A1 (zh) 一种芳香化合物、其制备方法及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40014275

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210607

Address after: Victoria, Australia

Applicant after: Golden oaks treatment Ltd.

Address before: New South Wales Australia

Applicant before: THE University OF SYDNEY